F 15845 is a potent and persistent blocker of the sodium current. It possesses cardioprotective properties and exhibits both anti-ischemic activity and short- and long-term cardioprotection following myocardial infarction. Furthermore, F 15845 finds utility in the investigation of myocardial functional impairment [1].

F 15845 (10 nM-10 μM) concentration-dependently reduces veratrine-induced diastolic contracture with an IC 50 value of 0.14 μM in isolated atria [1]. F 15845 (0.1-10 μM) preserves viability in isolated cardiomyocytes exposed to lysophosphatidylcholine (LPC) [1]. F 15845 (0.3 μM) significantly counteracts [Na + ] increase during no-flow ischemia [1]. F 15845 (0.3 μM, 0-35 min) delays the reduction in [Na + ], but marks and maintains upon reperfusion [1].

F 15845 (i.v.; 5 mg/kg) exhibits remarkable cardioprotective properties in anesthetized rat [1]. Animal Model: Rat [1] Dosage: 2.5 mg/kg, 5 mg/kg Administration: intravenously Result: Significantly reduced infarct size, decreased of troponin I levels and limited the long-term expansion of infarct size.